Harbin Jixianglong Biotech Co., Ltd. - 723330 - 05/01/2026

Why It Matters

These violations expose U.S. patients to potentially unsafe peptide drugs and jeopardize the firm’s ability to sell in the lucrative GLP‑1 market, while highlighting regulatory scrutiny of overseas API suppliers.

Key Takeaways

• FDA placed firm on Import Alert 66‑40, removing Green List status
• Two relabeled semaglutide batches recalled after misbranding violations
• Quality unit lacked oversight for supplier qualification and batch traceability
• Process and cleaning validations missing for peptide API production
• Firm must submit CAPA, validation protocols, and water system monitoring

Pulse Analysis

The FDA’s enforcement action against Harbin Jixianglong Biotech underscores the heightened regulatory focus on active pharmaceutical ingredient (API) manufacturers, especially those supplying high‑demand peptide drugs such as semaglutide and tirzepatide. CGMP compliance is the backbone of drug safety, ensuring that every step—from raw material receipt to final release—meets stringent quality standards. When a firm bypasses approved supplier lists, alters labeling, or neglects required validations, it not only breaches legal obligations but also raises the risk of adulterated or misbranded products entering the U.S. market, potentially harming patients and eroding trust in the supply chain.

In this case, the company repackaged semaglutide from unregistered sources, falsified manufacturer information on labels, and failed to provide required drug‑listing data. The FDA responded by adding Harbin Jixianglong to Import Alert 66‑40, which subjects future shipments to detention without physical examination, and removed it from the Green List that previously facilitated smoother imports. The lack of process validation, inadequate cleaning studies, and insufficient water system monitoring further compounded the violations, prompting a voluntary recall of two batches and demanding a detailed corrective‑action and preventive‑action (CAPA) plan, validation reports, and risk assessments.

For the broader industry, this warning serves as a cautionary tale about the perils of cutting corners in quality oversight. Companies must invest in robust quality‑unit authority, maintain approved supplier registries, and rigorously validate manufacturing and cleaning processes to meet ICH Q7 and FDA expectations. Failure to do so can result in import alerts, product recalls, and loss of market access, especially in the competitive GLP‑1 space where demand is soaring. Engaging experienced CGMP consultants and strengthening internal audit mechanisms are prudent steps to mitigate regulatory risk and safeguard both patient safety and commercial viability.